Precision Biosciences (DTIL) Liabilities and Shareholders Equity (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $143.9 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 15.66% year-over-year to $143.9 million in Q1 2026; TTM through Mar 2026 was $500.7 million, a 13.64% decrease from a year earlier, with the FY2025 full-year figure at $154.4 million, up 13.22% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $143.9 million, down from $154.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for DTIL reached as high as $297.2 million in Q2 2022 and fell as low as $93.5 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $174.4 million across 5 years, with a median of $164.3 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity climbed 29.14% in 2022 and tumbled 39.52% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $238.2 million in 2022, then sank by 32.91% to $159.8 million in 2023, then dropped by 14.64% to $136.4 million in 2024, then gained by 13.22% to $154.4 million in 2025, then dropped by 6.82% to $143.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $143.9 million in Q1 2026, $154.4 million in Q4 2025, and $93.5 million in Q3 2025.